Foghorn Therapeutics, Inc. (FHTX)
|Net Income (ttm)||-58.06M|
|Trading Day||January 15|
|Day's Range||18.54 - 20.05|
|52-Week Range||15.12 - 25.88|
US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeScie...
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetical...
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetical...
Foghorn Therapeutics Files Terms For $120 Million IPO
Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to...
Foghorn Therapeutics, a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The com... [Read more...]
|IPO Date |
Oct 23, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is 25.00, which is an increase of 28.07% from the latest price.